ANAB vs RCUS vs ARQT vs DAWN vs FOLD

For growth investors, AnaptysBio, Inc.

(ANAB) is the stronger pick with 157. 0% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Analysts rate AnaptysBio, Inc. (ANAB) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, AnaptysBio, Inc.

(ANAB) delivered a total return of +283. 9%, compared to -39. 5% for Arcutis Biotherapeutics, Inc. (ARQT). Over 10 years, the gap is even starker: ANAB returned +491. 0% versus DAWN's -8. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Day One Biopharmaceuticals, Inc.

(DAWN) is the lower-risk stock at 0. 35β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 451% more volatile than DAWN relative to the S&P 500. On balance sheet safety, Day One Biopharmaceuticals, Inc. (DAWN) carries a lower debt/equity ratio of 1% versus 176% for Amicus Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AnaptysBio, Inc.

(ANAB) is pulling ahead at 157. 0% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: AnaptysBio, Inc. grew EPS 91. 0% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amicus Therapeutics, Inc.

(FOLD) is the more profitable company, earning -4. 3% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps -4. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANAB leads at 20. 4% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — ANAB leads at 99. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Amicus Therapeutics, Inc.

(FOLD) trades at 40. 6x forward P/E versus 77. 6x for Arcutis Biotherapeutics, Inc. — 37. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ARQT: 71. 8% to $35. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Day One Biopharmaceuticals, Inc.

(DAWN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 35)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DAWN: -8. 4%, RCUS: +45. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ANAB is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; DAWN is a small-cap high-growth stock; FOLD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.